All In Biotech

Drug Trial Radar · NCT07531433

Post-Trial Access to ATH434 for Patients With Multiple System Atrophy

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Alterity TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 15, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes

Summary

As written by the sponsor on the registry.

This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.

Conditions

  • Multiple System Atrophy

Interventions

  • ATH434Drug

    ATH434 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.